Issue link: https://www.e-digitaleditions.com/i/1138630
10 July 2019 Tablets & Capsules treatment, the donation will transition to supplying that product. FDA approves LEMS and heart disease treatments SILVER SPRING, MD—The FDA approved Ruzurgi (amifampridine) as the first and only pediatric treat- ment (ages 6 to 17) of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the connection between nerves and mus- cles. It is manufactured by Jacobus Pharmaceutical, Princeton, NJ. The agency also approved Vyn- daqel (tafamidis meglumine) and Vyndamax (tafamidis) to treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These drug products are the first FDA-approved treatments for ATTR-CM. They are manufactured by FoldRx, a subsidiary of Pfizer, New York, NY. IPEC publishes supply chain security position paper ARLINGTON, VA— The IPEC Federation has published a position paper on supply chain security for pharmaceutical grade excipients to provide support to excipient manu- facturers, distributors, pharmaceu- tical traders, brokers, carriers, and other service providers along the supply chain. The paper summa- rizes existing regulations and tools that support good practices for sup- ply chain security and drug safety, including IPEC's Good Distribution Practices Guide for Pharmaceutical Excipients and its Risk Assessment Guide. While the federation empha- sizes that supply chain responsibility ultimately remains with the finished dosage form manufacturer, the paper states that each participant in the supply chain has responsibilities for its own specific area of activity. FDA selects Merck, Walmart, IBM, and KPMG for blockchain pilot program SILVER SPRING, MD—The FDA has selected Merck, Walmart, IBM, and KPMG to evaluate the use of blockchain in securing the drug product supply chain. The compa- (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to the US Centers for Disease Control and Prevention (CDC) to support national efforts for preventing HIV. The company will provide the CDC up to 2.4 million bottles of Tru- vada annually for uninsured Americans at risk for HIV through 2030, making it one of the largest medication dona- tions in the US. If Gilead's Descovy (emtricitabine and tenofovir alafenam- ide) is approved by the FDA for PrEP Generic Drug Development web page. New functions added to the web page include text searching by active ingredient or by Reference Listed Drug/Reference Standard application number, search results filtering and exporting, and easy-to- follow navigation, among others. Gilead donates PrEP treatment to CDC FOSTER CITY, CA—Gilead Sci- ences has agreed to donate Truvada Benefit from the galenIQ™ effect. Less bitter, more pleasant. galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP). The easy to use filler-binder that makes medicine taste better.

